Last reviewed · How we verify

Ceftazidime Injection

Murdoch Childrens Research Institute · FDA-approved active Small molecule

Ceftazidime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.

Ceftazidime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Serious bacterial infections including pneumonia, meningitis, and intra-abdominal infections, Pseudomonas aeruginosa infections, Febrile neutropenia in immunocompromised patients.

At a glance

Generic nameCeftazidime Injection
SponsorMurdoch Childrens Research Institute
Drug classThird-generation cephalosporin
TargetPenicillin-binding proteins (PBPs)
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved

Mechanism of action

Ceftazidime works by disrupting the cross-linking of peptidoglycan in the bacterial cell wall, leading to cell wall instability and bacterial death. It has broad-spectrum activity against gram-negative and gram-positive bacteria, with particular efficacy against Pseudomonas aeruginosa. The drug is bactericidal and is commonly used to treat serious infections in hospitalized patients.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: